Analysts Issue Forecasts for Cabaletta Bio Q1 Earnings

Cabaletta Bio, Inc. (NASDAQ:CABA) – Research analysts at William Blair issued their Q1 2026 EPS estimates for shares of Cabaletta Bio in a research note issued on Tuesday, April 1st. William Blair analyst S. Corwin anticipates that the company will post earnings per share of ($0.71) for the quarter. The consensus estimate for Cabaletta Bio’s current full-year earnings is ($2.34) per share. William Blair also issued estimates for Cabaletta Bio’s Q2 2026 earnings at ($0.74) EPS and Q3 2026 earnings at ($0.72) EPS.

A number of other equities research analysts have also recently issued reports on CABA. Guggenheim reiterated a “buy” rating and issued a $23.00 target price on shares of Cabaletta Bio in a research note on Tuesday. Wells Fargo & Company dropped their price objective on shares of Cabaletta Bio from $6.00 to $3.00 and set an “equal weight” rating on the stock in a report on Tuesday. Morgan Stanley reduced their target price on shares of Cabaletta Bio from $30.00 to $22.00 and set an “overweight” rating for the company in a research note on Tuesday. Evercore ISI cut shares of Cabaletta Bio from an “outperform” rating to an “inline” rating and decreased their target price for the stock from $15.00 to $6.00 in a research report on Friday, December 20th. Finally, UBS Group cut their price target on Cabaletta Bio from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Cabaletta Bio has an average rating of “Buy” and a consensus price target of $21.00.

Cabaletta Bio Trading Down 6.7 %

Shares of NASDAQ CABA opened at $1.11 on Thursday. Cabaletta Bio has a 12-month low of $1.08 and a 12-month high of $19.04. The company has a market cap of $56.32 million, a price-to-earnings ratio of -0.52 and a beta of 2.44. The stock’s 50 day simple moving average is $1.98 and its 200 day simple moving average is $2.89.

Cabaletta Bio (NASDAQ:CABA) last issued its earnings results on Monday, March 31st. The company reported ($0.65) EPS for the quarter, meeting analysts’ consensus estimates of ($0.65).

Hedge Funds Weigh In On Cabaletta Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CABA. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Cabaletta Bio in the 3rd quarter valued at about $32,000. Point72 DIFC Ltd bought a new stake in shares of Cabaletta Bio in the 3rd quarter worth approximately $33,000. Miller Financial Services LLC bought a new stake in shares of Cabaletta Bio in the 4th quarter worth approximately $33,000. Avanza Fonder AB acquired a new stake in Cabaletta Bio during the fourth quarter valued at approximately $40,000. Finally, Intech Investment Management LLC boosted its holdings in Cabaletta Bio by 42.2% during the fourth quarter. Intech Investment Management LLC now owns 20,203 shares of the company’s stock worth $46,000 after buying an additional 5,999 shares in the last quarter.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.